The Effect of Bread Enriched With Portulaca Oleracea on Metabolic Control Indices in Patients With Type 2 Diabetes: a Parallel Randomized Clinical Trial
التفاصيل البيبلوغرافية
العنوان:
The Effect of Bread Enriched With Portulaca Oleracea on Metabolic Control Indices in Patients With Type 2 Diabetes: a Parallel Randomized Clinical Trial
Background: Diabetes is the most common chronic disease worldwide. Some herbs are used to control diabetes. Portulaca Oleracea is a type of plant that has essential fatty acid-rich leaves. Objectives: This study aimed to evaluate the effect of bread enriched with Portulaca Oleracea on metabolic control indices in patients with type 2.Methods: This parallel randomized controlled clinical trial was conducted on 104 patients with type 2 diabetes. Participants received bulk bread containing 10% Portulaca powder for 4 weeks (intervention group), the control group used their normal daily bread. At baseline and end of the study a 12 hours fasting and 2 hours later blood sample were collected to quantify plasma glucose levels and lipid profiles. The effectiveness of the intervention method was compared with the difference between the mean before and after the intervention (change score) in the two groups using t-test.Results: The results showed that after the intervention, a significant difference was found between Fasting blood sugar, cholesterol and high-density lipoprotein variables in intervention groups, but could not affect serum low-density lipoprotein, triglyceride levels, blood sugar and Glycated hemoglobin(HbA1C) It should be noted that the difference between the means of the two groups before and after the intervention indicates that there is a significant difference between the other groups except HbA1C. Conclusions: consumption of bread enriched with portulaca oleracea did have a significant impact on metabolic indices of diabetes and improvement lipid profile. It is recommended to use bread enriched with portulaca oleracea powder, areas where the staple food is bread.Trial registration in the Iranian clinical trial system with the code IRCT2011030309006010N1.
